Figure 5. C-term Shh Ab 1C11 – 2G4 treatment inhibits in vivo growth of NSCLC in a mouse xenograft model.

(A) 7-week-old female nude mice were inoculated with 10 × 10⁶ NSCLC A549 cells in the flank region to establish tumors and randomly assigned to treatment regimens of IgG control or Ab 1C11-2G4 (8 mg/kg × 3 times a week for 3 weeks, intratumorally). Changes in tumor volume of mice treated with the antibodies IgG control or Ab 1C11 – 2G4 (n = 5, p = 0.001) over the course of the study are shown. At the end point, tumor mass (B) was determined on harvested tumors by weighing (n = 5, p = 0.05). (C) Images of tumors collected from antibody-treated mice with their identifying ear-tag mouse numbers (#) showing a clear reduction in tumor volumes (D) calculated using the formula (V = L × W²) in Ab 1C11 – 2G4-treated mice when compared with the control IgG antibody.